VTVT vTv Therapeutics, Inc. Quick Ratio

The price trajectory of vTv Therapeutics Inc. (VTVT) demonstrates the current indicator 11.87. vTv Therapeutics Inc. (VTVT) develops innovative tablet-based therapies for type 1 diabetes, investing in the study of glucokinase. The business faces intense pressure from global behemoths that restrict market access through patents. The operating model relies on a lean management team and external contractors to conduct clinical trials.

VTVT: vTv Therapeutics Intermediate Coverage Ratio 07/04/2022 - 10/31/2026

Analytical breakdowns for vTv Therapeutics Inc.

- market value and analyst target forecast:

Price Chart vtvtherapeutics.com|VTVT - Consensus Target

- market capitalization data:

Market Capitalization vTv Therapeutics Inc|VTVT - Enterprise Value

- balance sheet net asset value indicators:

Accounting Value per Share vTv Therapeutics|VTVT - Accounting Value of Company|Market Value to Book Value Ratio vtvtherapeutics.com|VTVT - Cumulative Company Assets

- debt and liquidity data:

- earnings and valuation multiples information:

VTVT - Company Net Income

Fundamental company valuation:vTv Therapeutics, Inc. - VTVT

Flagship merchandise of vTv Therapeutics

The development of TTP399 for diabetics requires significant expenditures, making it critical to monitor the ability of vTv Therapeutics Inc. (VTVT) to cover short-term obligations using cash and accounts receivable, excluding illiquid inventories. By analyzing the quick liquidity structure, an investor assesses the business's real margin of safety in the face of potential financial shocks and default risks.

Competitor analysis